PharmaCyte Biotech Management
Management criteria checks 4/4
PharmaCyte Biotech's CEO is Josh Silverman, appointed in Oct 2022, has a tenure of 2.25 years. total yearly compensation is $787.92K, comprised of 46.3% salary and 53.7% bonuses, including company stock and options. directly owns 0.72% of the company’s shares, worth $83.00K. The average tenure of the management team and the board of directors is 6.1 years and 3 years respectively.
Key information
Josh Silverman
Chief executive officer
US$787.9k
Total compensation
| CEO salary percentage | 46.3% |
| CEO tenure | 2.3yrs |
| CEO ownership | 0.7% |
| Management average tenure | 6.1yrs |
| Board average tenure | 3yrs |
Recent management updates
Recent updates
PharmaCyte Biotech (NASDAQ:PMCB) Is In A Strong Position To Grow Its Business
Mar 22
PharmaCyte Biotech says CEO to step down, announces strategic review of business
Oct 07PharmaCyte Biotech reaches agreement with Iroquois to include 2 board of directors
Aug 15Is This A Good Time To Invest In PharmaCyte?
Jan 07PharmaCyte Biotech: Buy The 'Dump'
Aug 21CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Oct 31 2024 | n/a | n/a | US$9m |
| Jul 31 2024 | n/a | n/a | US$10m |
| Apr 30 2024 | US$788k | US$365k | -US$17m |
| Jan 31 2024 | n/a | n/a | -US$15m |
| Oct 31 2023 | n/a | n/a | -US$10m |
| Jul 31 2023 | n/a | n/a | -US$10m |
| Apr 30 2023 | US$198k | US$188k | -US$4m |
Compensation vs Market: Josh's total compensation ($USD787.92K) is about average for companies of similar size in the US market ($USD641.95K).
Compensation vs Earnings: Josh's compensation has been consistent with company performance over the past year.
CEO
Josh Silverman (54 yo)
2.3yrs
Tenure
US$787,923
Compensation
Mr. Joshua N. Silverman, also known as Josh, is Independent Chairman of the Board of Petros Pharmaceuticals, Inc. Mr. Joshua N. Silverman, also known as Josh, serves as an Independent Director at Femasys I...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Interim CEO | 2.3yrs | US$787.92k | 0.72% $ 83.0k | |
| Chief Financial Officer | 7.8yrs | US$586.56k | 0.15% $ 17.3k | |
| Consulting Chief Medical Officer | 4.4yrs | no data | no data | |
| Member of Medical & Scientific Advisory Board and Consultant | 9.2yrs | no data | no data |
6.1yrs
Average Tenure
66yo
Average Age
Experienced Management: PMCB's management team is seasoned and experienced (6.1 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Interim CEO | 2.4yrs | US$787.92k | 0.72% $ 83.0k | |
| Member of Medical & Scientific Advisory Board and Consultant | 9.2yrs | no data | no data | |
| Independent Director | 2.2yrs | US$290.00k | 0% $ 0 | |
| Member of Medical & Scientific Advisory Board | 8.7yrs | no data | no data | |
| Chairman of Medical & Scientific Advisory Board | 3yrs | US$16.76k | no data | |
| Independent Director | 7.5yrs | US$296.00k | 0.040% $ 4.7k | |
| Independent Director | 2.1yrs | US$265.00k | 0% $ 0 | |
| Member of Medical & Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 2.4yrs | US$290.00k | 0.72% $ 83.0k | |
| Member of Medical & Scientific Advisory Board | 5.5yrs | no data | no data |
3.0yrs
Average Tenure
64.5yo
Average Age
Experienced Board: PMCB's board of directors are considered experienced (3 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/08 01:07 |
| End of Day Share Price | 2025/01/08 00:00 |
| Earnings | 2024/10/31 |
| Annual Earnings | 2024/04/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
PharmaCyte Biotech, Inc. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Edward White | H.C. Wainwright & Co. |
| Dan Trang | Stonegate Capital Markets, Inc. |